Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
P/E ratio for Lucid Diagnostics Inc. (LUCD)
P/E ratio as of 2023: -1.12
According to Lucid Diagnostics Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.12. At the end of 2022 the company had a P/E ratio of -0.88.
P/E ratio history for Lucid Diagnostics Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.12 |
| 2022 | -0.88 |
| 2021 | -6.53 |
| 2020 | -52.54 |
| 2019 | -98.41 |
| 2018 | -386.38 |